Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Investors
Patients
HCPs
Worldwide
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Company Facts & Japan offices
History
Worldwide Offices
Executive Leadership
Positions
Takeda Global Headquarters
Life at Takeda
Design Concept
Where we work
Corporate Philosophy
Our People
Values and Corporate Governance
Corporate Governance
Risk & Crisis Management
Global Ethics & Compliance / Global Code of Conduct
Transparency Disclosures
From the CEO
Contact Us
Celebrating the grand opening of Takeda Global Headquarters
LEARN MORE
What We Do
Our Business
We will become a global, values-based, R&D-driven, biopharmaceutical leader
Learn more
Research & Development
Ecosystem for Health Innovation
Our Pipeline
Clinical Trials
Investigator Initiated Research
Takeda Ventures, Inc.
Areas of Focus
Oncology
Rare Diseases
Neuroscience
Gastroenterology
Plasma-Derived Therapies
Vaccines
Alliances & Partnerships
Partnering with Takeda
Our Products
Manufacturing
Innovation Story
Access to Medicines
Our Approach and Our Position
Hear from Patients
Driving Impact with Partners
Pre- Approval Access
Suppliers
Sustainable Procurement
Supplier Code of Conduct
Supplier Diversity
Pharmaceutical Supply Chain Initiative
Supplier Qualification & Due Diligence
Shire Supplier Information
Takeda Supplier Solutions Portal
T-CiRA
About T-CiRA
Leaders Message
What we do
Portfolios
Project members
Inside T-CiRA
Research Achievements
We focus on our core therapeutic areas.
LEARN MORE
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Innovation
Quality at Takeda
The Key Elements at the Heart of Our Innovation
Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade
Caring
Medicine for the World
Safeguarding Plant Diversity
Takeda at TICAD6
Going Beyond Medicines
Change the World
Healthcare for All
Shared Knowledge for a Better Life for All
Harnessing the Power of People to Transform Health Care
Improving Access to Healthcare in Remote Communities
Shifting paradigms of COVID-19 reflections from the 75th UN General Assembly
Heritage
Keys to Aging Gracefully
Harnessing the power of people to transform health care
LEARN MORE
Corporate Responsibility
Takeda's CSR
Takeda is committed to addressing the world’s biggest challenges to sustainable development over the long term.
LEARN MORE
Programs in Action
Takeda Chair in Global Child Health
Takeda Initiative for the Global Fund
Global CSR Program
Apply for Funding
Frequently Asked Questions
Leaders Driving Change
Sustainable Value Report
Human Rights
Labor
Environment
Commitment to Carbon Neutrality
Emission Reduction Targets
Anti-Corruption
TAKEDA LIFE THEATER
Partner with our Global CSR Program
LEARN MORE
HOME
Newsroom
News Releases
Share:
Newsroom
News Releases
Statements
In the News
Featured Topics
Corporate Materials
Social Media
Message from the CEO
News Releases
Enter
All
Last 12 months
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
December 2020
December 7, 2020
12/7/2020
Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders
December 4, 2020
12/4/2020
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
December 1, 2020
12/1/2020
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific
December 1, 2020
12/1/2020
World’s Leading Life Science Companies Now Enrolling COMMUNITY, A Global Platform Trial For Hospitalized Patients with COVID-19
November 2020
November 24, 2020
11/24/2020
Announcement of Making Nihon Pharmaceutical Co., Ltd. a Wholly-owned Subsidiary Through Simple Share Exchange
November 13, 2020
11/13/2020
Final Results from the Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedema
November 5, 2020
11/5/2020
Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting
October 2020
October 29, 2020
10/29/2020
Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan
October 29, 2020
10/29/2020
Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
1
2
3
4
5
TOP